Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202830521> ?p ?o ?g. }
- W3202830521 endingPage "1457" @default.
- W3202830521 startingPage "1445" @default.
- W3202830521 abstract "Although trials with anti-seizure medications (ASMs) have not shown clear anti-epileptogenic or disease-modifying activity in humans to date, rapid advancements in genomic technology and emerging gene-mediated and gene replacement options offer hope for the successful development of disease-modifying therapies (DMTs) for genetic epilepsies. In fact, more than 26 potential DMTs are in various stages of preclinical and/or clinical development for genetic syndromes associated with epilepsy. The scope of disease-modification includes but is not limited to effects on the underlying pathophysiology, the condition's natural history, epilepsy severity, developmental achievement, function, behavior, sleep, and quality of life. While conventional regulatory clinical trials for epilepsy therapeutics have historically focused on seizure reduction, similarly designed trials may prove ill-equipped to identify these broader disease-modifying benefits. As we look forward to this pipeline of DMTs, focused consideration should be given to the challenges they pose to conventional clinical trial designs for epilepsy therapeutics. Just as DMTs promise to fundamentally alter how we approach the care of patients with genetic epilepsy syndromes, DMTs likewise challenge how we traditionally construct and measure the success of clinical trials. In the following, we briefly review the historical and preclinical frameworks for DMT development for genetic epilepsies and explore the many novel challenges posed for such trials, including the choice of suitable outcome measures, trial structure, timing and duration of treatment, feasible follow-up period, varying safety profile, and ethical concerns." @default.
- W3202830521 created "2021-10-11" @default.
- W3202830521 creator A5030421378 @default.
- W3202830521 creator A5037953901 @default.
- W3202830521 creator A5067016209 @default.
- W3202830521 date "2021-07-01" @default.
- W3202830521 modified "2023-09-30" @default.
- W3202830521 title "Clinical Trial Design for Disease-Modifying Therapies for Genetic Epilepsies" @default.
- W3202830521 cites W144303070 @default.
- W3202830521 cites W1554576051 @default.
- W3202830521 cites W1569672756 @default.
- W3202830521 cites W1572262481 @default.
- W3202830521 cites W1576891234 @default.
- W3202830521 cites W1602997642 @default.
- W3202830521 cites W1682509945 @default.
- W3202830521 cites W1756081881 @default.
- W3202830521 cites W1963479646 @default.
- W3202830521 cites W1964366976 @default.
- W3202830521 cites W1964895339 @default.
- W3202830521 cites W1974841170 @default.
- W3202830521 cites W1995505488 @default.
- W3202830521 cites W2008449504 @default.
- W3202830521 cites W2016942235 @default.
- W3202830521 cites W2017220638 @default.
- W3202830521 cites W2019879904 @default.
- W3202830521 cites W2021074267 @default.
- W3202830521 cites W2025181667 @default.
- W3202830521 cites W2033494215 @default.
- W3202830521 cites W2035882325 @default.
- W3202830521 cites W2041302667 @default.
- W3202830521 cites W2058147010 @default.
- W3202830521 cites W2060985684 @default.
- W3202830521 cites W2071899720 @default.
- W3202830521 cites W2073324225 @default.
- W3202830521 cites W2074790959 @default.
- W3202830521 cites W2075999647 @default.
- W3202830521 cites W2076018693 @default.
- W3202830521 cites W2082171245 @default.
- W3202830521 cites W2094044192 @default.
- W3202830521 cites W2105423985 @default.
- W3202830521 cites W2106179013 @default.
- W3202830521 cites W2109170426 @default.
- W3202830521 cites W2141778163 @default.
- W3202830521 cites W2146590936 @default.
- W3202830521 cites W2146721597 @default.
- W3202830521 cites W2153199755 @default.
- W3202830521 cites W2154277730 @default.
- W3202830521 cites W2155388782 @default.
- W3202830521 cites W2160653335 @default.
- W3202830521 cites W2166210432 @default.
- W3202830521 cites W2169266966 @default.
- W3202830521 cites W2169966598 @default.
- W3202830521 cites W2195799296 @default.
- W3202830521 cites W2320299399 @default.
- W3202830521 cites W2338814967 @default.
- W3202830521 cites W2358803561 @default.
- W3202830521 cites W2410408003 @default.
- W3202830521 cites W2488393817 @default.
- W3202830521 cites W2509522099 @default.
- W3202830521 cites W2537989343 @default.
- W3202830521 cites W2559901472 @default.
- W3202830521 cites W2582534361 @default.
- W3202830521 cites W2598352451 @default.
- W3202830521 cites W2726405642 @default.
- W3202830521 cites W2733418771 @default.
- W3202830521 cites W2766832340 @default.
- W3202830521 cites W2768490835 @default.
- W3202830521 cites W2788817175 @default.
- W3202830521 cites W2790333198 @default.
- W3202830521 cites W2790548666 @default.
- W3202830521 cites W2799850385 @default.
- W3202830521 cites W2807232570 @default.
- W3202830521 cites W2883928481 @default.
- W3202830521 cites W2895927020 @default.
- W3202830521 cites W2900805725 @default.
- W3202830521 cites W2901536632 @default.
- W3202830521 cites W2904426893 @default.
- W3202830521 cites W2924873081 @default.
- W3202830521 cites W2941342380 @default.
- W3202830521 cites W2941480208 @default.
- W3202830521 cites W2947259937 @default.
- W3202830521 cites W2958456424 @default.
- W3202830521 cites W2963252304 @default.
- W3202830521 cites W2964306335 @default.
- W3202830521 cites W2966208621 @default.
- W3202830521 cites W2967739194 @default.
- W3202830521 cites W2971450631 @default.
- W3202830521 cites W3005123902 @default.
- W3202830521 cites W3027203309 @default.
- W3202830521 cites W3034116567 @default.
- W3202830521 cites W3092161933 @default.
- W3202830521 cites W3099195036 @default.
- W3202830521 cites W3101814316 @default.
- W3202830521 cites W3103554383 @default.
- W3202830521 cites W3111050257 @default.
- W3202830521 cites W3114779957 @default.
- W3202830521 cites W3206994722 @default.
- W3202830521 cites W330343617 @default.